Endocrine Abstracts

Introduction: The recombinant GH receptor antagonist pegvisomant (PGV) is actually used for the treatment of acromegaly when surgery and medical therapy with somatostatin analogues (SSA) have failed. Long term safety and effectiveness need to be evaluated.Material and methods: Retrospective analysis of clinical data from all patients treated with pegvisomant in a pituitary disorders unit.Results: Thirteen patients are being treated...

Introduction: Patients with bariatric surgery require close monitoring because of possible metabolic complications. It has been published some cases of severe and persistent hypoglycemias resistant to diet and pharmacologic treatment being necessary a pancreatectomy. We present a case report of nesidioblastosis after gastric bypass that required subtotal pancreatectomy but despite this, hypoglycemias persisted. Before performing total pancreatectomy we placed a tube feeding in...

Introduction: Protocols for identifing and managing hyperglycemia and diabetes in hospital are necessary. Glycemic goals in non critical inpatients are:140 mg/ml(preprandial) and 180(posprandial),oral antidiabetic drug(OADs) withdrawn, avoid hypoglycemias, basal/bolus insulin (nor sliding scale) and request glycosylated haemoglobin.Aims: To evaluate the implementation of a protocol for management of diabetes(PHD) during the years 2009 and 2010 in our Hos...

Introduction: The autosomal dominant multiple endocrine neoplasia type 1 (MEN1), characterized by parathyroid hyperplasia (PH), neuroendocrine digestive tumours (NET) and pituitary adenomas (PA), is due to mutations in the tumor suppressor gene MEN1 encoding a 610-amino acid protein, menin. Guidelines recommend MEN1 mutational analysis in index cases with two or more MEN1-associated tumours, in first-degree relatives of mutation carriers and when clinical dat...